{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:57:23Z","timestamp":1787054243424,"version":"build-2736575974"},"reference-count":30,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T00:00:00Z","timestamp":1464220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.clinthera.2016.05.005","type":"journal-article","created":{"date-parts":[[2016,6,8]],"date-time":"2016-06-08T16:55:21Z","timestamp":1465404921000},"page":"1686-1695.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Proportion and Characteristics of Patients in Sweden Remaining at High Risk of Fracture Despite Prior Treatment"],"prefix":"10.1016","volume":"38","author":[{"given":"Dan","family":"Mellstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Po Steve","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Waern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Sajjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Salomonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.05.005_bib1","unstructured":"World Health Organization, WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Summary meeting report. WHO Press, World Health Organization. 2004. WHO Press."},{"key":"10.1016\/j.clinthera.2016.05.005_bib3","first-page":"137","article-title":"Osteoporosis in the European Union: a compendium of country-specific reports","volume":"8","author":"Svedbom","year":"2013","journal-title":"ArchOsteoporos"},{"key":"10.1016\/j.clinthera.2016.05.005_bib4","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.bone.2007.02.027","article-title":"The societal burden of osteoporosis in Sweden","volume":"40","author":"Borgstrom","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2016.05.005_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women","volume":"24","author":"Kanis","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2016.05.005_bib6","unstructured":"Quantify Research. Swedish Osteoporosis Care: Challenges and change management. Quantify Research. 2014 2014; http:\/\/www.quantifyresearch.com\/wp-content\/uploads\/2014\/06\/QR-Report-Swedish-Osteoporosis-Care-Final.pdf."},{"key":"10.1016\/j.clinthera.2016.05.005_bib7","unstructured":"Organization WH. FRAX\u00ae WHO Fracture Risk Assessment Tool. WHO. 2014. http:\/\/www.shef.ac.uk\/FRAX\/."},{"key":"10.1016\/j.clinthera.2016.05.005_bib8","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00198-008-0659-2","article-title":"Inadequate responders to osteoporosis treatment: proposal for an operational definition","volume":"19","author":"Diez-Perez","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2016.05.005_bib9","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00198-014-2619-3","article-title":"Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis","volume":"25","author":"Cairoli","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2016.05.005_bib10","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00198-012-2093-8","article-title":"Treatment failure in osteoporosis","volume":"23","author":"Diez-Perez","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2016.05.005_bib11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.05.005_bib12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2016.05.005_bib13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.05.005_bib14","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2016.05.005_bib15","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.05.005_bib16","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00198-008-0566-6","article-title":"Osteoporosis treatment and fracture incidence: the ICARO longitudinal study","volume":"19","author":"Adami","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2016.05.005_bib17","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","article-title":"The 25(OH)D level needed to maintain a favorable bisphosphonate response is >\/=33 ng\/ml","volume":"23","author":"Carmel","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2016.05.005_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2474-3-6","article-title":"Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates","volume":"3","author":"Heckman","year":"2002","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.clinthera.2016.05.005_bib19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bone.2012.03.026","article-title":"25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis","volume":"51","author":"Peris","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.clinthera.2016.05.005_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/jbmr.2011","article-title":"Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study","volume":"29","author":"Prieto-Alhambra","year":"2014","journal-title":"J Bone MinerRes"},{"key":"10.1016\/j.clinthera.2016.05.005_bib21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1385\/JCD:6:4:315","article-title":"What predicts early fracture or bone loss on bisphosphonate therapy?","volume":"6","author":"Sawka","year":"2003","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.clinthera.2016.05.005_bib22","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","article-title":"A systematic review of hip fracture incidence and probability of fracture worldwide","volume":"23","author":"Kanis","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2016.05.005_bib23","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/qjmed\/hcl073","article-title":"Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)","volume":"99","author":"Jakob","year":"2006","journal-title":"QJM"},{"key":"10.1016\/j.clinthera.2016.05.005_bib24","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-007-0506-x","article-title":"Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women","volume":"19","author":"Rabenda","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2016.05.005_bib25","unstructured":"Gliklich R, Dreyer N, Leavy M. Analysis of Linked Registry Data Sets. Registries for Evaluating Patient Outcomes: A User\u05f3s Guide [Internet] Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 [updated 2015]. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK208629\/."},{"key":"10.1016\/j.clinthera.2016.05.005_bib26","unstructured":"Adachi J, Goltzman D, Modi A, et al. Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study (abstract). Session: Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More. 2014. Abstract 48."},{"key":"10.1016\/j.clinthera.2016.05.005_bib27","unstructured":"Imel E, Eckert G, Modi A, Krishna A, Li Z, et al. SUN-0259: A Proportion of Osteoporotic Women Remains at Risk for Fractures Despite Adherence to Oral Bisphosphonates. Endocrine Society\u05f3s 96th Annual Meeting and Expo, June 21-24, 2014 - Chicago."},{"key":"10.1016\/j.clinthera.2016.05.005_bib28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1185\/03007995.2015.1016606","article-title":"Osteoporotic fracture rate among women with at least 1 year of adherence to osteoporosis treatment","volume":"31","author":"Modi","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2016.05.005_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(07)61342-7","article-title":"Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis","volume":"370","author":"Tang","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.05.005_bib30","series-title":"Diagnosis and treatment of osteoporosis. Institute for Clinical Systems Improvement (ICSI)","author":"Florence","year":"2013"},{"key":"10.1016\/j.clinthera.2016.05.005_bib31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s001980200053","article-title":"An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture","volume":"13","author":"Chevalley","year":"2002","journal-title":"Osteoporosis Int"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0149291816303393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0149291816303393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T11:59:03Z","timestamp":1498305543000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816303393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0149291816303393"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.05.005","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proportion and Characteristics of Patients in Sweden Remaining at High Risk of Fracture Despite Prior Treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.clinthera.2016.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors and Merck Sharp & Dohme Corp. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}